Lorus Signs Agreement With Japan's Sumitomo and Koken
Lorus Therapeutics, a biopharmaceutical company specializing in the research,
development and commercialization of pharmaceutical products and technologies
for the management of cancer, announced that it has signed a collaboration agreement
with Japan's leading pharmaceutical company, Sumitomo Pharmaceuticals and Koken.
According to terms of the agreement, Lorus will provide Sumitomo proprietary
antisense oligonucleotides complementary to Thioredoxin mRNA, specifically the
lead drug candidate, GTI-2601.